Company performance
Current Price
as of Jan 15, 2025$30.18
P/E Ratio
N/A
Market Cap
$4.7B
Description
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Metrics
Overview
- HQMorrisville, NC
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerTGTX
- Price$30.18+1.48%
Trading Information
- Market cap$4.70B
- Float90.27%
- Average Daily Volume (1m)2,522,702
- Average Daily Volume (3m)3,019,470
- EPS-$0.10
Company
- Revenue$264.79M
- Rev growth (1yr)-49.41%
- Net income$3.88M
- Gross margin88.79%
- EBITDA margin14.90%
- EBITDA$12.50M
- EV$3.67B
- EV/Revenue13.87
- P/EN/A
- P/S18.32
- P/B24.47
Documents
SEC Filings
Earnings Calls